Department of Biophysics, School of Life Science & Technology, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, PR China.
Center for Information in Biology, University of Electronic Science & Technology of China, Chengdu 610054, Sichuan, PR China.
Nanomedicine (Lond). 2018 Mar 1;13(6):595-603. doi: 10.2217/nnm-2017-0315. Epub 2018 Jan 30.
To enhance synergistic therapeutic effects in breast cancer therapy. Here, we used hollow mesoporous silica nanoparticles as a biocompatible carrier to coload chemotherapy drugs Irinotecan and near-infrared IR-820 dye, which enhanced antitumor efficacy by combining chemotherapy and phototherapy.
The successful synthesis of hollow mesoporous silica nanoparticles/Irinotecan/IR820 (HMII) nanocomplex was confirmed by Fourier transform infrared spectroscopy and Fluorescence spectra. The photothermal conversion efficiency and antitumor efficiency in murine breast cancer cells (EMT-6) bearing mice were further evaluated.
The results demonstrated that HMII enhanced the delivery of Irinotecan and IR-820 into EMT-6 cells. HMII generated a high temperature upon a near-infrared laser irradiation (808 nm), and showed higher therapeutic efficacy in EMT-6-bearing mice compared with either HMII without laser or free drug with a laser.
HMII is a desired drug codelivery system to efficiently inhibit the growth of breast cancer.
提高乳腺癌治疗的协同治疗效果。在这里，我们使用中空介孔硅纳米粒子作为生物相容性载体来共载化疗药物伊立替康和近红外 IR-820 染料，通过化疗和光疗相结合来增强抗肿瘤疗效。
通过傅里叶变换红外光谱和荧光光谱证实了中空介孔硅纳米粒子/伊立替康/IR820（HMII）纳米复合物的成功合成。进一步评估了其在携带小鼠乳腺癌细胞（EMT-6）的小鼠中的光热转换效率和抗肿瘤效率。
结果表明，HMII 增强了伊立替康和 IR-820 进入 EMT-6 细胞的递送。HMII 在近红外激光照射（808nm）下产生高温，并在 EMT-6 荷瘤小鼠中显示出比没有激光的 HMII 或带激光的游离药物更高的治疗效果。
HMII 是一种理想的药物共递药系统，可有效抑制乳腺癌的生长。
